Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics has announced a clinical supply agreement with Cyclotek for the radiolabeling of its RAD402 compound with Terbium-161, supporting the initiation of a Phase 1 clinical trial in prostate cancer in Australia. This agreement marks a significant milestone for Radiopharm as it moves towards ethics approval and the commencement of its first company-sponsored Phase I trial using 161Tb, potentially enhancing its market position in oncology radiopharmaceuticals.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas with high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies for use in cancer treatment.
Average Trading Volume: 3,742,165
Technical Sentiment Signal: Sell
Current Market Cap: A$56.76M
See more insights into RAD stock on TipRanks’ Stock Analysis page.